NASH (NON-ALCOHOLIC STEATOHEPATITIS)

Clinical trials for NASH (NON-ALCOHOLIC STEATOHEPATITIS) explained in plain language.

Never miss a new study

Get alerted when new NASH (NON-ALCOHOLIC STEATOHEPATITIS) trials appear

Sign up with your email to follow new studies for NASH (NON-ALCOHOLIC STEATOHEPATITIS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for MASH: phase 3 trial aims to shrink liver fat

Disease control Not yet recruiting

This study tests a new medicine called HSK31679 for people with MASH, a serious liver condition linked to metabolic issues. About 400 adults will receive either the drug or a placebo for 52 weeks to see if it safely reduces liver fat. The goal is to find a treatment that controls…

Matched conditions: NASH (NON-ALCOHOLIC STEATOHEPATITIS)

Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control

Last updated May 26, 2026 12:05 UTC

NASH (NON-ALCOHOLIC STEATOHEPATITIS)

Get alerted when new NASH (NON-ALCOHOLIC STEATOHEPATITIS) trials appear

New hope for MASH: phase 3 trial aims to shrink liver fat